New Delhi, Jul 18 (UNI) Bangalore-based Biopharma major Biocon Ltd today said it has launched Abraxane in the country with the US-based Abraxis Inc for the treatment of breast cancer.
''Abraxane is a significant advance in taxane therapy for the treatment of breast cancer. The product, available in the country as a single use 100 mg vial, eliminates the need for chemical solvents and allows for higher doses of paclitaxel without compromising safety and tolerability,'' the company said in a statement.
In August 2007, Abraxis established a licensing agreement with Biocon for commercialisation of the product in India.
Under the terms of agreement, Biocon has the right to market Abraxane in India, Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia, Kuwait, and certain other South Asian and Persian Gulf countries.
UNI SG AK HS1758